| 吉西他滨低剂量延时输注的研究进展 |
| |
| 引用本文： | 赵德华,楚明明,陈静,龚晶淼,孙丽琼,罗文,曹莉莎,刘真宏,王继生. 吉西他滨低剂量延时输注的研究进展[J]. 中国现代应用药学, 2018, 35(7): 1107-1111 |
| |
| 作者姓名： | 赵德华 楚明明 陈静 龚晶淼 孙丽琼 罗文 曹莉莎 刘真宏 王继生 |
| |
| 作者单位： | 绵阳市第三人民医院临床药学科, 四川 绵阳 621000,第三军医大学第二附属医院临床药学科, 重庆 400037,绵阳市第三人民医院临床药学科, 四川 绵阳 621000,绵阳市第三人民医院临床药学科, 四川 绵阳 621000,绵阳市第三人民医院临床药学科, 四川 绵阳 621000,绵阳市第三人民医院临床药学科, 四川 绵阳 621000,绵阳市第三人民医院临床药学科, 四川 绵阳 621000,绵阳市第三人民医院临床药学科, 四川 绵阳 621000,绵阳市第三人民医院临床药学科, 四川 绵阳 621000 |
| |
| 摘 要： | 吉西他滨（gemcitabine，GEM）为抗嘧啶核苷酸代谢类药物。目前，GEM的标准给药方式为1 000~1 250 mg·m-2，30 min静脉快速输注。但是，药理学研究表明，GEM延时输注可使细胞内有活性的GEM三磷酸盐达到最佳的蓄积速度，提示GEM延时输注在药动学方面要优于30 min快速输注。故本文对GEM低剂量延时输注的相关研究进行综述，以期为临床用药提供相关依据。
|
| 关 键 词： | 吉西他滨 低剂量 快速输注 延时输注 药动学 |
| 收稿时间： | 2017-07-15 |
| 修稿时间： | 2018-07-02 |
Research Progress of Prolonged Low-dose Infusion for Gemcitabine |
| |
| ZHAO Dehu,CHU Mingming,CHEN Jing,GONG Jingmiao,SUN Liqiong,LUO Wen,CAO Lish,LIU Zhenhong and WANG Jisheng. Research Progress of Prolonged Low-dose Infusion for Gemcitabine[J]. The Chinese Journal of Modern Applied Pharmacy, 2018, 35(7): 1107-1111 |
| |
| Authors: | ZHAO Dehu CHU Mingming CHEN Jing GONG Jingmiao SUN Liqiong LUO Wen CAO Lish LIU Zhenhong WANG Jisheng |
| |
| Affiliation: | Department of Clinical Pharmacy, The Third Hospital of Mianyang, Mianyang 621000, China,Department of Clinical Pharmacy, The Second Affiliated Hospital of Third Military Medical University, Chongqing 400037, China,Department of Clinical Pharmacy, The Third Hospital of Mianyang, Mianyang 621000, China,Department of Clinical Pharmacy, The Third Hospital of Mianyang, Mianyang 621000, China,Department of Clinical Pharmacy, The Third Hospital of Mianyang, Mianyang 621000, China,Department of Clinical Pharmacy, The Third Hospital of Mianyang, Mianyang 621000, China,Department of Clinical Pharmacy, The Third Hospital of Mianyang, Mianyang 621000, China,Department of Clinical Pharmacy, The Third Hospital of Mianyang, Mianyang 621000, China and Department of Clinical Pharmacy, The Third Hospital of Mianyang, Mianyang 621000, China |
| |
| Abstract: | Gemcitabine(GEM) is a kind of anti-pyrimidine nucleotide metabolism drug. At present, the standard dose of GEM is 1 000-1 250 mg·m-2, intravenous infusion for 30 min. However, pharmacological studies have shown that GEM with prolonged infusion can improve the accumulation rate of GEM triphosphate(dFdCTP), suggesting that prolonged infusion of GEM is superior to 30 min infusion in pharmacokinetics. This paper review the related research of GEM with prolonged low-dose infusion in order to provide the basis for it''s clinical medication. |
| |
| Keywords: | Gemcitabine low-dose rapid infusion prolonged infusion pharmacokinetics |
|
| 点击此处可从《中国现代应用药学》浏览原始摘要信息 |
|
点击此处可从《中国现代应用药学》下载全文 |
|
